| Source : |
HEK293 |
| Species : |
Human |
| Tag : |
His |
| Form : |
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant. |
| Bio-activity : |
Immobilized Human VEGF165, premium grade at 2 μg/mL (100 μL/well) can bind Human VEGF R2, His Tag with a linear range of 10-156 ng/mL. Immobilized Human VEGF R2, His Tag at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF165, His,Avitag with a linear range of 2-39 ng/mL. Immobilized Human VEGF R2, His Tag at 2 μg/mL (100 μL/well), can bind pre-mixed increasing concentrations of Bevacizumab and 0.05 μg/mL (100 μL/well) Biotinylated Human VEGF165, His,Avitag with a half maximal inhibitory concentration (IC50) of 0.74 μg/mL. |
| Molecular Mass : |
This protein carries a polyhistidine tag at the C-terminusThe protein has a calculated MW of 85.2 kDa. The protein migrates as 105-150 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. |
| Proteinlength : |
Ala20-Glu764 |
| Endotoxin : |
Less than 1.0 EU per μg by the LAL method. |
| Purity : |
>90% as determined by SDS-PAGE. >90% as determined by SEC-MALS. |
| Storage : |
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles. |
| Reconstitution : |
It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents. |
